Scott BJ, Klein AV, Wang J. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of cinically relevant differences and indication extrapolation. J Clin Pharmacol. 2015;55(Supl.3):S123-32. https://doi.org/10.1002/jcph.339

World Health Organization. Guidelines on evaluation of similar biotherapeutic products. Geneva: World Health Organization; 2009.

FDA Guidance for Industry. Scientific considerations in demonstrating biosimilarity to a reference product. HHS FDA/CDER/CBER, Apr. 2015. Disponible en: https://www.fda.gov/downloads/drugs/guidances/ucm291128.pdf

European Medicines Agency. Guideline on similar biological medicinal products containing biotechnologyderived proteins as active substance: non-clinical and clinical issues, Feb. 2006 Disponble en: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf

European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies - nonclinical and clinical issues. May 2012. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf

Ministerio de Salud y Protección Social. Decreto1782 de 2014. Fecha de consulta: 12 de junio 2018: Disponible en: https://www.minsalud.gov.co/Normatividad.../Decreto%201782%20de%202014.pdf.